GSK-923295: Potent Small-Molecule CENP-E Inhibitor for Mitotic Arrest

Executive Summary: GSK-923295 is a nanomolar inhibitor of the mitotic kinesin CENP-E, acting via suppression of microtubule-stimulated ATPase activity to arrest cells in mitosis (APExBIO, product page). The compound exhibits a median GI₅₀ of 32 nM across diverse tumor lines, with dose-dependent antitumor efficacy observed in colon tumor xenograft models (Wood et al., 2010, PubMed). CENP-E connects mitotic checkpoint signaling to chromosome alignment, a process critical for mitotic fidelity and regulated by centromere function (Walsh et al., 2026, J Cell Sci). GSK-923295's effects recapitulate CENP-E knockdown phenotypes, making it valuable for mechanistic studies in cell cycle and cancer research (APExBIO). The compound requires specific solubility and storage conditions, and is not intended for diagnostic or clinical use.

Biological Rationale

Mitosis ensures accurate segregation of the duplicated genome between daughter cells. This process depends on the mitotic spindle, which attaches to kinetochores at centromeres on chromosomes (Walsh et al., 2026, J Cell Sci). Centromere-associated protein E (CENP-E) is a kinesin motor protein essential for chromosome congression and alignment at the metaphase plate (Kapoor et al., 2006, Cell). Loss or inhibition of CENP-E disrupts chromosome alignment, leading to mitotic errors and potential aneuploidy (Walsh et al., 2026). Such errors are implicated in tumorigenesis and cancer progression (Levine & Holland, 2018, Cell). CTCF, a chromatin-organizing protein, maintains centromere function and mitotic fidelity, partially through its influence on CENP-E recruitment and centromere structure (Walsh et al., 2026). Targeting CENP-E with selective inhibitors like GSK-923295 allows researchers to dissect the mitotic checkpoint signaling pathway and model mitotic arrest in cancer cells.

Mechanism of Action of GSK-923295

GSK-923295 is a small-molecule inhibitor with a Ki value of 3.2 nM for CENP-E (APExBIO, product page). The compound suppresses the microtubule-stimulated ATPase activity of CENP-E, stabilizing the ATP-bound state and slowing ADP and inorganic phosphate release (Wood et al., 2010). This inhibition leads to mitotic arrest at metaphase, preventing the transition to anaphase (Kapoor et al., 2006). Morphological changes in treated cells, including broadened metaphase plates and increased intercentromere distances, mimic those seen with CENP-E RNAi knockdown (Walsh et al., 2026). The molecular weight is 592.14 Da, and GSK-923295 is highly soluble in DMSO (≥29.6 mg/mL) and ethanol (≥14.87 mg/mL with ultrasonic assistance), but insoluble in water (APExBIO).

Evidence & Benchmarks

• GSK-923295 inhibits CENP-E ATPase activity with a Ki of 3.2 nM, confirmed by in vitro enzymatic assays (Wood et al., 2010, PubMed).
• Across 237 tumor cell lines, GSK-923295 exhibits an average GI₅₀ of 253 nM and a median GI₅₀ of 32 nM under standard in vitro conditions (APExBIO, product page).
• In vivo, 125 mg/kg intraperitoneal administration in mice with Colo205 colon tumor xenografts produced dose-dependent antitumor responses, including partial and complete regressions (Wood et al., 2010, PubMed).
• GSK-923295 treatment induces apoptosis and mitotic arrest, as evidenced by increased mitotic figures and apoptotic markers in tumor tissues (Wood et al., 2010, PubMed).
• Phenotypic effects of GSK-923295 closely resemble CENP-E knockdown, including improper chromosome alignment and spindle defects (Walsh et al., 2026, J Cell Sci).

This article extends prior reviews such as GSK-923295: Small-Molecule CENP-E Inhibitor for Mitotic Arrest by integrating quantitative benchmarks and recent centromere biology, clarifying the mechanistic links to CTCF and mitotic fidelity. It also updates the workflow guidance of GSK-923295: A Small-Molecule CENP-E Inhibitor Transforming Cell Cycle Studies by emphasizing solubility limits, apoptosis endpoints, and the need for rapid solution use to prevent compound degradation.

Applications, Limits & Misconceptions

GSK-923295 is suited for research in:

• Dissecting the mitotic checkpoint signaling pathway.
• Modeling cell cycle arrest and chromosome alignment defects.
• In vitro and in vivo cancer research workflows, particularly colon cancer xenografts.
• High-content screening for mitosis-targeted anticancer agents.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: GSK-923295 from APExBIO is for research use only and not approved for clinical or diagnostic applications (APExBIO).
• Solubility limitations: The compound is insoluble in water; use DMSO or ethanol (with ultrasound) for solution preparation.
• Stability concerns: Solutions should be used promptly after preparation to avoid degradation; store powder at -20°C.
• Cell-type specific outcomes: Not all tumor lines respond equally; GI₅₀ varies, and some cells with redundant mitotic pathways may show partial resistance.
• Does not mimic complete CENP-E knockout: Phenotypes may reflect partial inhibition and may not recapitulate all genetic knockout effects, especially in centromere biology.

Workflow Integration & Parameters

GSK-923295 can be integrated into standard cell cycle analysis and cancer research protocols:

• Prepare stock solutions in DMSO (≥29.6 mg/mL) or ethanol (≥14.87 mg/mL with ultrasonic assistance).
• Store dry powder at -20°C; avoid repeated freeze-thaw cycles.
• Apply to cells at concentrations ranging from 10 nM to 1 μM for in vitro assays; titrate as needed for cell line sensitivity.
• For in vivo studies, 125 mg/kg by intraperitoneal injection in mice has been validated in colon tumor xenograft models.
• Monitor endpoints including mitotic index, chromosome alignment, apoptosis, and cell viability (Wood et al., 2010).

This article clarifies and updates the practical parameters discussed in GSK-923295: A Next-Generation CENP-E Inhibitor for Cancer Research by emphasizing rapid solution use and the impact of centromere maintenance proteins like CTCF on phenotypic outcomes.

Conclusion & Outlook

GSK-923295 is a validated research tool for investigating mitotic checkpoint signaling and chromosome alignment in cancer models. Its potency and specificity for CENP-E enable precise modulation of mitotic fidelity, with robust benchmarks in both cell lines and xenograft models. Future research may leverage GSK-923295 for synthetic lethality screens, combinatorial therapies, and advanced studies of centromere biology, including the interplay with CTCF and cohesin. As with all APExBIO research products, adherence to recommended storage and handling protocols is essential for experimental reproducibility.